Search results
Results from the WOW.Com Content Network
By 2008 Glenmark was the fifth-biggest pharmaceutical company in India. [5] By 2011 the founder of the company was one of the richest men in India, [6] and Glenmark had worldwide sales of $778 million, a 37% increase over the last year's sales; the growth was driven by Glenmark's entry into the US and European generics markets. [7]
The following is a list of the 20 largest settlements reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2013, ordered by the size of the total settlement. The settlement amount includes both the civil (False Claims Act) settlement and criminal fine.
German pharmaceutical and chemical company Merck KGaA will pay $280 million to settle a claim brought against a former subsidiary, Dey Pharma, regarding Medicare and Medicaid reimbursements, the U ...
Peachtree provides cash to personal injury, product liability, and wrongful death plaintiffs while their case is either still pending or, if successful, awaiting settlement payment. Sometimes a plaintiff may be forced to settle their case early for less cash than they deserve, because they have been unable to work due to their injury.
On Monday, Ligand Pharmaceuticals (NAS: LGND) confirmed that Merck (NYS: MRK) will pay it a $2 million milestone payment, as the latter begins phase 2b/3 clinical trials of a new cancer drug.
The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare ...
Blue Cross Blue Shield will soon begin paying out $2.67 billion to customers follow a years-long lawsuit alleging that the health insurance giant broke antitrust laws.. The litigation began in ...
insurers. Such payments can also distort the marketplace by providing an unfair competitive edge to the company making the payments, regardless of the relative therapeutic value of the company’s products. Finally, corrupt payments can compromise medical research independence and the standards of scientific integrity.